Novel Molecular Targets for Ductal Carcinoma In Situ (DCIS)

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

October 1, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Breast Cancer
Interventions
OTHER

Biomarkers

Evaluate the intracellular and intraluminal distribution of autophagy and calcium efflux markers in each breast lesion in comparison to the HER2, proliferation (Ki-67, PCNA), p53, inflammatory, and apoptotic (Annexin-1) markers in the same patient. Determine the qualitative amount and localization of PMCA2 and Vitamin D Receptor in each breast lesion with intraductal calcium spicules compared to lesions without microcalcifications.

Trial Locations (1)

23606

Sentara Surgery Specialists and Dorothy G Hoefer Comprehensive Breast Center, Newport News

All Listed Sponsors
collaborator

George Mason University

OTHER

collaborator

Dorothy G. Hoefer Foundation

OTHER

lead

Sentara Norfolk General Hospital

OTHER

NCT03148015 - Novel Molecular Targets for Ductal Carcinoma In Situ (DCIS) | Biotech Hunter | Biotech Hunter